Global Bursitis Treatment
Global Bursitis Treatment

Bursitis Treatment Comprehensive Study by Type (Corticosteroids {Dexamethasone, Prednisolone}, Antibiotic {Flucloxacillin, Erythromycin, Clarithromycin}, Analgesics, Others), Diagnosis (X-Ray, Ultrasound), Route of Administration (Oral, Topical), Treatment (Medication, Surgery {Corticosteroid Injection}), End User (Hospitals & Clinics, Diagnostic Centers, Research Centers) Players and Region - Global Market Outlook to 2024

Bursitis Treatment Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 215 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

Bursitis is an inflammation that affects the joints. Bursae are fluid-filled bags that serve as a barrier between bones, tendons, joints, and muscles. Bursitis most occurs in various parts of the body such as shoulders, elbows, ankles, knees, buttocks, hips and thighs. Some of the self-treatment regarding bursitis disease are ice packs, painkillers, raising the affected area and others. Major symptoms of bursitis are pain that increases with movement or pressure, swelling, loss of movement, redness in the affected area, affected area feels hot when touched and others. The demand for Bursitis treatment has increased, due to the rising number of geriatric population. For instance, according to the government of the United States, in 2015, more than 47.8 million people have age 65 and older in the United States. Therefore, increasing the old age population and rising disposable income in developing countries may drive the market in the future.

The market study is being classified by Type (Corticosteroids {Dexamethasone, Prednisolone}, Antibiotic {Flucloxacillin, Erythromycin, Clarithromycin}, Analgesics and Others) and major geographies with country level break-up.

Novartis AG (Switzerland), Pfizer Inc. (United States), Amgen Inc. (United States), AVEO Pharmaceuticals, Inc. (United States), Bayer AG (Germany), Bellicum Pharmaceuticals Inc. (United States), MediaPharma s.r.l. (Italy), Teva Pharmaceutical Industries Ltd. (Israel), Crecent Therapeutics (India) and Arinna Lifesciences Private (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Sun Pharmaceutical Industries (India), Bioanalytical Systems, Inc. (United States), Perrigo Company (Ireland) and Arbor Pharmaceuticals (United States).

The global bursitis treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Bursitis Treatment market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Bursitis Treatment market by Type, Application and Region.

On the basis of geography, the market of Bursitis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing geriatric population across the world
  • Increasing Number of Sport-Related Injuries

Market Trend
  • Technology Advancement regarding Bursitis Treatment

Restraints
  • Stringent Government Regulation and issue related to Side Effect of Drugs

Opportunities
  • Increasing Demand from Emerging Market such a China, India and Others

Challenges
  • Lack of Awareness Regarding Treatment and the High Cost of the Treatment Methods





Key Target Audience
Bursitis Treatment Companies, Medical Research Laboratories, Research and Development (R&D) Companies, Market Research and Consulting Service Providers, Potential Investors and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Corticosteroids {Dexamethasone, Prednisolone}
  • Antibiotic {Flucloxacillin, Erythromycin, Clarithromycin}
  • Analgesics
  • Others
By Diagnosis
  • X-Ray
  • Ultrasound

By Route of Administration
  • Oral
  • Topical

By Treatment
  • Medication
  • Surgery {Corticosteroid Injection}

By End User
  • Hospitals & Clinics
  • Diagnostic Centers
  • Research Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing geriatric population across the world
      • 3.2.2. Increasing Number of Sport-Related Injuries
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness Regarding Treatment and the High Cost of the Treatment Methods
    • 3.4. Market Trends
      • 3.4.1. Technology Advancement regarding Bursitis Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bursitis Treatment, by Type, Diagnosis , Route of Administration, Treatment, End User and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Bursitis Treatment (Value)
      • 5.2.1. Global Bursitis Treatment by: Type (Value)
        • 5.2.1.1. Corticosteroids {Dexamethasone, Prednisolone}
        • 5.2.1.2. Antibiotic {Flucloxacillin, Erythromycin, Clarithromycin}
        • 5.2.1.3. Analgesics
        • 5.2.1.4. Others
      • 5.2.2. Global Bursitis Treatment by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Topical
      • 5.2.3. Global Bursitis Treatment by: Treatment (Value)
        • 5.2.3.1. Medication
        • 5.2.3.2. Surgery {Corticosteroid Injection}
      • 5.2.4. Global Bursitis Treatment by: End User (Value)
        • 5.2.4.1. Hospitals & Clinics
        • 5.2.4.2. Diagnostic Centers
        • 5.2.4.3. Research Centers
      • 5.2.5. Global Bursitis Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Bursitis Treatment (Volume)
      • 5.3.1. Global Bursitis Treatment by: Type (Volume)
        • 5.3.1.1. Corticosteroids {Dexamethasone, Prednisolone}
        • 5.3.1.2. Antibiotic {Flucloxacillin, Erythromycin, Clarithromycin}
        • 5.3.1.3. Analgesics
        • 5.3.1.4. Others
      • 5.3.2. Global Bursitis Treatment by: Route of Administration (Volume)
        • 5.3.2.1. Oral
        • 5.3.2.2. Topical
      • 5.3.3. Global Bursitis Treatment by: Treatment (Volume)
        • 5.3.3.1. Medication
        • 5.3.3.2. Surgery {Corticosteroid Injection}
      • 5.3.4. Global Bursitis Treatment by: End User (Volume)
        • 5.3.4.1. Hospitals & Clinics
        • 5.3.4.2. Diagnostic Centers
        • 5.3.4.3. Research Centers
      • 5.3.5. Global Bursitis Treatment Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Bursitis Treatment (Price)
      • 5.4.1. Global Bursitis Treatment by: Type (Price)
  • 6. Bursitis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AVEO Pharmaceuticals, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bellicum Pharmaceuticals Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. MediaPharma s.r.l. (Italy)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Crecent Therapeutics (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Arinna Lifesciences Private (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Bursitis Treatment Sale, by Type, Diagnosis , Route of Administration, Treatment, End User and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Bursitis Treatment (Value)
      • 7.2.1. Global Bursitis Treatment by: Type (Value)
        • 7.2.1.1. Corticosteroids {Dexamethasone, Prednisolone}
        • 7.2.1.2. Antibiotic {Flucloxacillin, Erythromycin, Clarithromycin}
        • 7.2.1.3. Analgesics
        • 7.2.1.4. Others
      • 7.2.2. Global Bursitis Treatment by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Topical
      • 7.2.3. Global Bursitis Treatment by: Treatment (Value)
        • 7.2.3.1. Medication
        • 7.2.3.2. Surgery {Corticosteroid Injection}
      • 7.2.4. Global Bursitis Treatment by: End User (Value)
        • 7.2.4.1. Hospitals & Clinics
        • 7.2.4.2. Diagnostic Centers
        • 7.2.4.3. Research Centers
      • 7.2.5. Global Bursitis Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Bursitis Treatment (Volume)
      • 7.3.1. Global Bursitis Treatment by: Type (Volume)
        • 7.3.1.1. Corticosteroids {Dexamethasone, Prednisolone}
        • 7.3.1.2. Antibiotic {Flucloxacillin, Erythromycin, Clarithromycin}
        • 7.3.1.3. Analgesics
        • 7.3.1.4. Others
      • 7.3.2. Global Bursitis Treatment by: Route of Administration (Volume)
        • 7.3.2.1. Oral
        • 7.3.2.2. Topical
      • 7.3.3. Global Bursitis Treatment by: Treatment (Volume)
        • 7.3.3.1. Medication
        • 7.3.3.2. Surgery {Corticosteroid Injection}
      • 7.3.4. Global Bursitis Treatment by: End User (Volume)
        • 7.3.4.1. Hospitals & Clinics
        • 7.3.4.2. Diagnostic Centers
        • 7.3.4.3. Research Centers
      • 7.3.5. Global Bursitis Treatment Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Bursitis Treatment (Price)
      • 7.4.1. Global Bursitis Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bursitis Treatment: by Type(USD Million)
  • Table 2. Bursitis Treatment Corticosteroids {Dexamethasone, Prednisolone} , by Region USD Million (2013-2018)
  • Table 3. Bursitis Treatment Antibiotic {Flucloxacillin, Erythromycin, Clarithromycin} , by Region USD Million (2013-2018)
  • Table 4. Bursitis Treatment Analgesics , by Region USD Million (2013-2018)
  • Table 5. Bursitis Treatment Others , by Region USD Million (2013-2018)
  • Table 6. Bursitis Treatment: by Route of Administration(USD Million)
  • Table 7. Bursitis Treatment Oral , by Region USD Million (2013-2018)
  • Table 8. Bursitis Treatment Topical , by Region USD Million (2013-2018)
  • Table 9. Bursitis Treatment: by Treatment(USD Million)
  • Table 10. Bursitis Treatment Medication , by Region USD Million (2013-2018)
  • Table 11. Bursitis Treatment Surgery {Corticosteroid Injection} , by Region USD Million (2013-2018)
  • Table 12. Bursitis Treatment: by End User(USD Million)
  • Table 13. Bursitis Treatment Hospitals & Clinics , by Region USD Million (2013-2018)
  • Table 14. Bursitis Treatment Diagnostic Centers , by Region USD Million (2013-2018)
  • Table 15. Bursitis Treatment Research Centers , by Region USD Million (2013-2018)
  • Table 16. South America Bursitis Treatment, by Country USD Million (2013-2018)
  • Table 17. South America Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 18. South America Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 19. South America Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 20. South America Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 21. South America Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 22. Brazil Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 23. Brazil Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 24. Brazil Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 25. Brazil Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 26. Brazil Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 27. Argentina Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 28. Argentina Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 29. Argentina Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 30. Argentina Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 31. Argentina Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 32. Rest of South America Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 33. Rest of South America Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 34. Rest of South America Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 35. Rest of South America Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 36. Rest of South America Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 37. Asia Pacific Bursitis Treatment, by Country USD Million (2013-2018)
  • Table 38. Asia Pacific Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 39. Asia Pacific Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 40. Asia Pacific Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 41. Asia Pacific Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 42. Asia Pacific Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 43. China Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 44. China Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 45. China Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 46. China Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 47. China Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 48. Japan Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 49. Japan Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 50. Japan Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 51. Japan Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 52. Japan Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 53. India Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 54. India Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 55. India Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 56. India Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 57. India Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 58. South Korea Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 59. South Korea Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 60. South Korea Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 61. South Korea Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 62. South Korea Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 63. Taiwan Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 64. Taiwan Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 65. Taiwan Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 66. Taiwan Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 67. Taiwan Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 68. Australia Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 69. Australia Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 70. Australia Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 71. Australia Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 72. Australia Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 73. Rest of Asia-Pacific Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 74. Rest of Asia-Pacific Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 75. Rest of Asia-Pacific Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 76. Rest of Asia-Pacific Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 77. Rest of Asia-Pacific Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 78. Europe Bursitis Treatment, by Country USD Million (2013-2018)
  • Table 79. Europe Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 80. Europe Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 81. Europe Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 82. Europe Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 83. Europe Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 84. Germany Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 85. Germany Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 86. Germany Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 87. Germany Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 88. Germany Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 89. France Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 90. France Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 91. France Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 92. France Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 93. France Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 94. Italy Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 95. Italy Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 96. Italy Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 97. Italy Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 98. Italy Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 99. United Kingdom Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 100. United Kingdom Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 101. United Kingdom Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 102. United Kingdom Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 103. United Kingdom Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 104. Netherlands Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 105. Netherlands Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 106. Netherlands Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 107. Netherlands Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 108. Netherlands Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 109. Rest of Europe Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 110. Rest of Europe Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 111. Rest of Europe Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 112. Rest of Europe Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 113. Rest of Europe Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 114. MEA Bursitis Treatment, by Country USD Million (2013-2018)
  • Table 115. MEA Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 116. MEA Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 117. MEA Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 118. MEA Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 119. MEA Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 120. Middle East Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 121. Middle East Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 122. Middle East Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 123. Middle East Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 124. Middle East Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 125. Africa Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 126. Africa Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 127. Africa Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 128. Africa Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 129. Africa Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 130. North America Bursitis Treatment, by Country USD Million (2013-2018)
  • Table 131. North America Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 132. North America Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 133. North America Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 134. North America Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 135. North America Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 136. United States Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 137. United States Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 138. United States Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 139. United States Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 140. United States Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 141. Canada Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 142. Canada Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 143. Canada Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 144. Canada Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 145. Canada Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 146. Mexico Bursitis Treatment, by Type USD Million (2013-2018)
  • Table 147. Mexico Bursitis Treatment, by Diagnosis USD Million (2013-2018)
  • Table 148. Mexico Bursitis Treatment, by Route of Administration USD Million (2013-2018)
  • Table 149. Mexico Bursitis Treatment, by Treatment USD Million (2013-2018)
  • Table 150. Mexico Bursitis Treatment, by End User USD Million (2013-2018)
  • Table 151. Bursitis Treatment Sales: by Type(M Tons)
  • Table 152. Bursitis Treatment Sales Corticosteroids {Dexamethasone, Prednisolone} , by Region M Tons (2013-2018)
  • Table 153. Bursitis Treatment Sales Antibiotic {Flucloxacillin, Erythromycin, Clarithromycin} , by Region M Tons (2013-2018)
  • Table 154. Bursitis Treatment Sales Analgesics , by Region M Tons (2013-2018)
  • Table 155. Bursitis Treatment Sales Others , by Region M Tons (2013-2018)
  • Table 156. Bursitis Treatment Sales: by Route of Administration(M Tons)
  • Table 157. Bursitis Treatment Sales Oral , by Region M Tons (2013-2018)
  • Table 158. Bursitis Treatment Sales Topical , by Region M Tons (2013-2018)
  • Table 159. Bursitis Treatment Sales: by Treatment(M Tons)
  • Table 160. Bursitis Treatment Sales Medication , by Region M Tons (2013-2018)
  • Table 161. Bursitis Treatment Sales Surgery {Corticosteroid Injection} , by Region M Tons (2013-2018)
  • Table 162. Bursitis Treatment Sales: by End User(M Tons)
  • Table 163. Bursitis Treatment Sales Hospitals & Clinics , by Region M Tons (2013-2018)
  • Table 164. Bursitis Treatment Sales Diagnostic Centers , by Region M Tons (2013-2018)
  • Table 165. Bursitis Treatment Sales Research Centers , by Region M Tons (2013-2018)
  • Table 166. South America Bursitis Treatment Sales, by Country M Tons (2013-2018)
  • Table 167. South America Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 168. South America Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 169. South America Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 170. South America Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 171. South America Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 172. Brazil Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 173. Brazil Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 174. Brazil Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 175. Brazil Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 176. Brazil Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 177. Argentina Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 178. Argentina Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 179. Argentina Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 180. Argentina Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 181. Argentina Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 182. Rest of South America Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 183. Rest of South America Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 184. Rest of South America Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 185. Rest of South America Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 186. Rest of South America Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 187. Asia Pacific Bursitis Treatment Sales, by Country M Tons (2013-2018)
  • Table 188. Asia Pacific Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 189. Asia Pacific Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 190. Asia Pacific Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 191. Asia Pacific Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 192. Asia Pacific Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 193. China Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 194. China Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 195. China Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 196. China Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 197. China Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 198. Japan Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 199. Japan Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 200. Japan Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 201. Japan Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 202. Japan Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 203. India Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 204. India Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 205. India Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 206. India Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 207. India Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 208. South Korea Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 209. South Korea Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 210. South Korea Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 211. South Korea Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 212. South Korea Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 213. Taiwan Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 214. Taiwan Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 215. Taiwan Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 216. Taiwan Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 217. Taiwan Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 218. Australia Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 219. Australia Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 220. Australia Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 221. Australia Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 222. Australia Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 223. Rest of Asia-Pacific Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 224. Rest of Asia-Pacific Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 225. Rest of Asia-Pacific Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 226. Rest of Asia-Pacific Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 227. Rest of Asia-Pacific Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 228. Europe Bursitis Treatment Sales, by Country M Tons (2013-2018)
  • Table 229. Europe Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 230. Europe Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 231. Europe Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 232. Europe Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 233. Europe Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 234. Germany Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 235. Germany Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 236. Germany Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 237. Germany Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 238. Germany Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 239. France Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 240. France Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 241. France Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 242. France Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 243. France Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 244. Italy Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 245. Italy Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 246. Italy Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 247. Italy Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 248. Italy Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 249. United Kingdom Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 250. United Kingdom Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 251. United Kingdom Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 252. United Kingdom Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 253. United Kingdom Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 254. Netherlands Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 255. Netherlands Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 256. Netherlands Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 257. Netherlands Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 258. Netherlands Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 259. Rest of Europe Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 260. Rest of Europe Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 261. Rest of Europe Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 262. Rest of Europe Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 263. Rest of Europe Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 264. MEA Bursitis Treatment Sales, by Country M Tons (2013-2018)
  • Table 265. MEA Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 266. MEA Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 267. MEA Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 268. MEA Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 269. MEA Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 270. Middle East Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 271. Middle East Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 272. Middle East Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 273. Middle East Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 274. Middle East Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 275. Africa Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 276. Africa Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 277. Africa Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 278. Africa Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 279. Africa Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 280. North America Bursitis Treatment Sales, by Country M Tons (2013-2018)
  • Table 281. North America Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 282. North America Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 283. North America Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 284. North America Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 285. North America Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 286. United States Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 287. United States Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 288. United States Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 289. United States Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 290. United States Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 291. Canada Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 292. Canada Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 293. Canada Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 294. Canada Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 295. Canada Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 296. Mexico Bursitis Treatment Sales, by Type M Tons (2013-2018)
  • Table 297. Mexico Bursitis Treatment Sales, by Diagnosis M Tons (2013-2018)
  • Table 298. Mexico Bursitis Treatment Sales, by Route of Administration M Tons (2013-2018)
  • Table 299. Mexico Bursitis Treatment Sales, by Treatment M Tons (2013-2018)
  • Table 300. Mexico Bursitis Treatment Sales, by End User M Tons (2013-2018)
  • Table 301. Bursitis Treatment: by Type(USD/Units)
  • Table 302. Company Basic Information, Sales Area and Its Competitors
  • Table 303. Company Basic Information, Sales Area and Its Competitors
  • Table 304. Company Basic Information, Sales Area and Its Competitors
  • Table 305. Company Basic Information, Sales Area and Its Competitors
  • Table 306. Company Basic Information, Sales Area and Its Competitors
  • Table 307. Company Basic Information, Sales Area and Its Competitors
  • Table 308. Company Basic Information, Sales Area and Its Competitors
  • Table 309. Company Basic Information, Sales Area and Its Competitors
  • Table 310. Company Basic Information, Sales Area and Its Competitors
  • Table 311. Company Basic Information, Sales Area and Its Competitors
  • Table 312. Bursitis Treatment: by Type(USD Million)
  • Table 313. Bursitis Treatment Corticosteroids {Dexamethasone, Prednisolone} , by Region USD Million (2019-2024)
  • Table 314. Bursitis Treatment Antibiotic {Flucloxacillin, Erythromycin, Clarithromycin} , by Region USD Million (2019-2024)
  • Table 315. Bursitis Treatment Analgesics , by Region USD Million (2019-2024)
  • Table 316. Bursitis Treatment Others , by Region USD Million (2019-2024)
  • Table 317. Bursitis Treatment: by Route of Administration(USD Million)
  • Table 318. Bursitis Treatment Oral , by Region USD Million (2019-2024)
  • Table 319. Bursitis Treatment Topical , by Region USD Million (2019-2024)
  • Table 320. Bursitis Treatment: by Treatment(USD Million)
  • Table 321. Bursitis Treatment Medication , by Region USD Million (2019-2024)
  • Table 322. Bursitis Treatment Surgery {Corticosteroid Injection} , by Region USD Million (2019-2024)
  • Table 323. Bursitis Treatment: by End User(USD Million)
  • Table 324. Bursitis Treatment Hospitals & Clinics , by Region USD Million (2019-2024)
  • Table 325. Bursitis Treatment Diagnostic Centers , by Region USD Million (2019-2024)
  • Table 326. Bursitis Treatment Research Centers , by Region USD Million (2019-2024)
  • Table 327. South America Bursitis Treatment, by Country USD Million (2019-2024)
  • Table 328. South America Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 329. South America Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 330. South America Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 331. South America Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 332. South America Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 333. Brazil Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 334. Brazil Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 335. Brazil Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 336. Brazil Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 337. Brazil Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 338. Argentina Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 339. Argentina Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 340. Argentina Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 341. Argentina Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 342. Argentina Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 343. Rest of South America Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 344. Rest of South America Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 345. Rest of South America Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 346. Rest of South America Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 347. Rest of South America Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 348. Asia Pacific Bursitis Treatment, by Country USD Million (2019-2024)
  • Table 349. Asia Pacific Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 350. Asia Pacific Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 351. Asia Pacific Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 352. Asia Pacific Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 353. Asia Pacific Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 354. China Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 355. China Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 356. China Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 357. China Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 358. China Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 359. Japan Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 360. Japan Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 361. Japan Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 362. Japan Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 363. Japan Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 364. India Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 365. India Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 366. India Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 367. India Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 368. India Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 369. South Korea Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 370. South Korea Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 371. South Korea Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 372. South Korea Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 373. South Korea Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 374. Taiwan Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 375. Taiwan Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 376. Taiwan Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 377. Taiwan Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 378. Taiwan Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 379. Australia Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 380. Australia Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 381. Australia Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 382. Australia Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 383. Australia Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 384. Rest of Asia-Pacific Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 385. Rest of Asia-Pacific Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 386. Rest of Asia-Pacific Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 387. Rest of Asia-Pacific Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 388. Rest of Asia-Pacific Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 389. Europe Bursitis Treatment, by Country USD Million (2019-2024)
  • Table 390. Europe Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 391. Europe Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 392. Europe Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 393. Europe Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 394. Europe Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 395. Germany Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 396. Germany Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 397. Germany Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 398. Germany Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 399. Germany Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 400. France Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 401. France Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 402. France Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 403. France Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 404. France Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 405. Italy Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 406. Italy Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 407. Italy Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 408. Italy Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 409. Italy Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 410. United Kingdom Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 411. United Kingdom Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 412. United Kingdom Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 413. United Kingdom Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 414. United Kingdom Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 415. Netherlands Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 416. Netherlands Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 417. Netherlands Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 418. Netherlands Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 419. Netherlands Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 420. Rest of Europe Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 421. Rest of Europe Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 422. Rest of Europe Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 423. Rest of Europe Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 424. Rest of Europe Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 425. MEA Bursitis Treatment, by Country USD Million (2019-2024)
  • Table 426. MEA Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 427. MEA Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 428. MEA Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 429. MEA Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 430. MEA Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 431. Middle East Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 432. Middle East Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 433. Middle East Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 434. Middle East Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 435. Middle East Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 436. Africa Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 437. Africa Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 438. Africa Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 439. Africa Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 440. Africa Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 441. North America Bursitis Treatment, by Country USD Million (2019-2024)
  • Table 442. North America Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 443. North America Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 444. North America Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 445. North America Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 446. North America Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 447. United States Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 448. United States Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 449. United States Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 450. United States Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 451. United States Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 452. Canada Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 453. Canada Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 454. Canada Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 455. Canada Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 456. Canada Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 457. Mexico Bursitis Treatment, by Type USD Million (2019-2024)
  • Table 458. Mexico Bursitis Treatment, by Diagnosis USD Million (2019-2024)
  • Table 459. Mexico Bursitis Treatment, by Route of Administration USD Million (2019-2024)
  • Table 460. Mexico Bursitis Treatment, by Treatment USD Million (2019-2024)
  • Table 461. Mexico Bursitis Treatment, by End User USD Million (2019-2024)
  • Table 462. Bursitis Treatment Sales: by Type(M Tons)
  • Table 463. Bursitis Treatment Sales Corticosteroids {Dexamethasone, Prednisolone} , by Region M Tons (2019-2024)
  • Table 464. Bursitis Treatment Sales Antibiotic {Flucloxacillin, Erythromycin, Clarithromycin} , by Region M Tons (2019-2024)
  • Table 465. Bursitis Treatment Sales Analgesics , by Region M Tons (2019-2024)
  • Table 466. Bursitis Treatment Sales Others , by Region M Tons (2019-2024)
  • Table 467. Bursitis Treatment Sales: by Route of Administration(M Tons)
  • Table 468. Bursitis Treatment Sales Oral , by Region M Tons (2019-2024)
  • Table 469. Bursitis Treatment Sales Topical , by Region M Tons (2019-2024)
  • Table 470. Bursitis Treatment Sales: by Treatment(M Tons)
  • Table 471. Bursitis Treatment Sales Medication , by Region M Tons (2019-2024)
  • Table 472. Bursitis Treatment Sales Surgery {Corticosteroid Injection} , by Region M Tons (2019-2024)
  • Table 473. Bursitis Treatment Sales: by End User(M Tons)
  • Table 474. Bursitis Treatment Sales Hospitals & Clinics , by Region M Tons (2019-2024)
  • Table 475. Bursitis Treatment Sales Diagnostic Centers , by Region M Tons (2019-2024)
  • Table 476. Bursitis Treatment Sales Research Centers , by Region M Tons (2019-2024)
  • Table 477. South America Bursitis Treatment Sales, by Country M Tons (2019-2024)
  • Table 478. South America Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 479. South America Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 480. South America Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 481. South America Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 482. South America Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 483. Brazil Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 484. Brazil Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 485. Brazil Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 486. Brazil Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 487. Brazil Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 488. Argentina Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 489. Argentina Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 490. Argentina Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 491. Argentina Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 492. Argentina Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 493. Rest of South America Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 494. Rest of South America Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 495. Rest of South America Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 496. Rest of South America Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 497. Rest of South America Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 498. Asia Pacific Bursitis Treatment Sales, by Country M Tons (2019-2024)
  • Table 499. Asia Pacific Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 500. Asia Pacific Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 501. Asia Pacific Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 502. Asia Pacific Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 503. Asia Pacific Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 504. China Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 505. China Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 506. China Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 507. China Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 508. China Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 509. Japan Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 510. Japan Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 511. Japan Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 512. Japan Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 513. Japan Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 514. India Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 515. India Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 516. India Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 517. India Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 518. India Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 519. South Korea Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 520. South Korea Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 521. South Korea Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 522. South Korea Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 523. South Korea Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 524. Taiwan Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 525. Taiwan Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 526. Taiwan Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 527. Taiwan Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 528. Taiwan Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 529. Australia Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 530. Australia Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 531. Australia Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 532. Australia Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 533. Australia Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 534. Rest of Asia-Pacific Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 535. Rest of Asia-Pacific Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 536. Rest of Asia-Pacific Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 537. Rest of Asia-Pacific Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 538. Rest of Asia-Pacific Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 539. Europe Bursitis Treatment Sales, by Country M Tons (2019-2024)
  • Table 540. Europe Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 541. Europe Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 542. Europe Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 543. Europe Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 544. Europe Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 545. Germany Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 546. Germany Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 547. Germany Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 548. Germany Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 549. Germany Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 550. France Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 551. France Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 552. France Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 553. France Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 554. France Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 555. Italy Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 556. Italy Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 557. Italy Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 558. Italy Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 559. Italy Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 560. United Kingdom Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 561. United Kingdom Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 562. United Kingdom Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 563. United Kingdom Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 564. United Kingdom Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 565. Netherlands Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 566. Netherlands Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 567. Netherlands Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 568. Netherlands Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 569. Netherlands Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 570. Rest of Europe Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 571. Rest of Europe Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 572. Rest of Europe Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 573. Rest of Europe Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 574. Rest of Europe Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 575. MEA Bursitis Treatment Sales, by Country M Tons (2019-2024)
  • Table 576. MEA Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 577. MEA Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 578. MEA Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 579. MEA Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 580. MEA Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 581. Middle East Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 582. Middle East Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 583. Middle East Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 584. Middle East Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 585. Middle East Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 586. Africa Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 587. Africa Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 588. Africa Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 589. Africa Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 590. Africa Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 591. North America Bursitis Treatment Sales, by Country M Tons (2019-2024)
  • Table 592. North America Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 593. North America Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 594. North America Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 595. North America Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 596. North America Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 597. United States Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 598. United States Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 599. United States Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 600. United States Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 601. United States Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 602. Canada Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 603. Canada Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 604. Canada Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 605. Canada Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 606. Canada Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 607. Mexico Bursitis Treatment Sales, by Type M Tons (2019-2024)
  • Table 608. Mexico Bursitis Treatment Sales, by Diagnosis M Tons (2019-2024)
  • Table 609. Mexico Bursitis Treatment Sales, by Route of Administration M Tons (2019-2024)
  • Table 610. Mexico Bursitis Treatment Sales, by Treatment M Tons (2019-2024)
  • Table 611. Mexico Bursitis Treatment Sales, by End User M Tons (2019-2024)
  • Table 612. Bursitis Treatment: by Type(USD/Units)
  • Table 613. Research Programs/Design for This Report
  • Table 614. Key Data Information from Secondary Sources
  • Table 615. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bursitis Treatment: by Type USD Million (2013-2018)
  • Figure 5. Global Bursitis Treatment: by Route of Administration USD Million (2013-2018)
  • Figure 6. Global Bursitis Treatment: by Treatment USD Million (2013-2018)
  • Figure 7. Global Bursitis Treatment: by End User USD Million (2013-2018)
  • Figure 8. South America Bursitis Treatment Share (%), by Country
  • Figure 9. Asia Pacific Bursitis Treatment Share (%), by Country
  • Figure 10. Europe Bursitis Treatment Share (%), by Country
  • Figure 11. MEA Bursitis Treatment Share (%), by Country
  • Figure 12. North America Bursitis Treatment Share (%), by Country
  • Figure 13. Global Bursitis Treatment: by Type M Tons (2013-2018)
  • Figure 14. Global Bursitis Treatment: by Route of Administration M Tons (2013-2018)
  • Figure 15. Global Bursitis Treatment: by Treatment M Tons (2013-2018)
  • Figure 16. Global Bursitis Treatment: by End User M Tons (2013-2018)
  • Figure 17. South America Bursitis Treatment Share (%), by Country
  • Figure 18. Asia Pacific Bursitis Treatment Share (%), by Country
  • Figure 19. Europe Bursitis Treatment Share (%), by Country
  • Figure 20. MEA Bursitis Treatment Share (%), by Country
  • Figure 21. North America Bursitis Treatment Share (%), by Country
  • Figure 22. Global Bursitis Treatment: by Type USD/Units (2013-2018)
  • Figure 23. Global Bursitis Treatment share by Players 2018 (%)
  • Figure 24. Global Bursitis Treatment share by Players (Top 3) 2018(%)
  • Figure 25. Global Bursitis Treatment share by Players (Top 5) 2018(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Novartis AG (Switzerland) Revenue: by Geography 2018
  • Figure 29. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc. (United States) Revenue: by Geography 2018
  • Figure 31. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Amgen Inc. (United States) Revenue: by Geography 2018
  • Figure 33. AVEO Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. AVEO Pharmaceuticals, Inc. (United States) Revenue: by Geography 2018
  • Figure 35. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Bayer AG (Germany) Revenue: by Geography 2018
  • Figure 37. Bellicum Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Bellicum Pharmaceuticals Inc. (United States) Revenue: by Geography 2018
  • Figure 39. MediaPharma s.r.l. (Italy) Revenue, Net Income and Gross profit
  • Figure 40. MediaPharma s.r.l. (Italy) Revenue: by Geography 2018
  • Figure 41. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 42. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2018
  • Figure 43. Crecent Therapeutics (India) Revenue, Net Income and Gross profit
  • Figure 44. Crecent Therapeutics (India) Revenue: by Geography 2018
  • Figure 45. Arinna Lifesciences Private (India) Revenue, Net Income and Gross profit
  • Figure 46. Arinna Lifesciences Private (India) Revenue: by Geography 2018
  • Figure 47. Global Bursitis Treatment: by Type USD Million (2019-2024)
  • Figure 48. Global Bursitis Treatment: by Route of Administration USD Million (2019-2024)
  • Figure 49. Global Bursitis Treatment: by Treatment USD Million (2019-2024)
  • Figure 50. Global Bursitis Treatment: by End User USD Million (2019-2024)
  • Figure 51. South America Bursitis Treatment Share (%), by Country
  • Figure 52. Asia Pacific Bursitis Treatment Share (%), by Country
  • Figure 53. Europe Bursitis Treatment Share (%), by Country
  • Figure 54. MEA Bursitis Treatment Share (%), by Country
  • Figure 55. North America Bursitis Treatment Share (%), by Country
  • Figure 56. Global Bursitis Treatment: by Type M Tons (2019-2024)
  • Figure 57. Global Bursitis Treatment: by Route of Administration M Tons (2019-2024)
  • Figure 58. Global Bursitis Treatment: by Treatment M Tons (2019-2024)
  • Figure 59. Global Bursitis Treatment: by End User M Tons (2019-2024)
  • Figure 60. South America Bursitis Treatment Share (%), by Country
  • Figure 61. Asia Pacific Bursitis Treatment Share (%), by Country
  • Figure 62. Europe Bursitis Treatment Share (%), by Country
  • Figure 63. MEA Bursitis Treatment Share (%), by Country
  • Figure 64. North America Bursitis Treatment Share (%), by Country
  • Figure 65. Global Bursitis Treatment: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Amgen Inc. (United States)
  • AVEO Pharmaceuticals, Inc. (United States)
  • Bayer AG (Germany)
  • Bellicum Pharmaceuticals Inc. (United States)
  • MediaPharma s.r.l. (Italy)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Crecent Therapeutics (India)
  • Arinna Lifesciences Private (India)
Additional players considered in the study are as follows:
Sun Pharmaceutical Industries (India) , Bioanalytical Systems, Inc. (United States) , Perrigo Company (Ireland) , Arbor Pharmaceuticals (United States) ,
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation